KR100781815B1 - 리네졸리드 결정 형태 ⅱ - Google Patents

리네졸리드 결정 형태 ⅱ Download PDF

Info

Publication number
KR100781815B1
KR100781815B1 KR1020027009923A KR20027009923A KR100781815B1 KR 100781815 B1 KR100781815 B1 KR 100781815B1 KR 1020027009923 A KR1020027009923 A KR 1020027009923A KR 20027009923 A KR20027009923 A KR 20027009923A KR 100781815 B1 KR100781815 B1 KR 100781815B1
Authority
KR
South Korea
Prior art keywords
delete delete
linezolide
methyl
phenyl
oxazolidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027009923A
Other languages
English (en)
Korean (ko)
Other versions
KR20020072300A (ko
Inventor
마이클 에스. 버그렌
Original Assignee
파마시아 앤드 업존 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22658183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100781815(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 파마시아 앤드 업존 캄파니 엘엘씨 filed Critical 파마시아 앤드 업존 캄파니 엘엘씨
Publication of KR20020072300A publication Critical patent/KR20020072300A/ko
Application granted granted Critical
Publication of KR100781815B1 publication Critical patent/KR100781815B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020027009923A 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ Expired - Fee Related KR100781815B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17983700P 2000-02-02 2000-02-02
US60/179,837 2000-02-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077016678A Division KR100864745B1 (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ

Publications (2)

Publication Number Publication Date
KR20020072300A KR20020072300A (ko) 2002-09-14
KR100781815B1 true KR100781815B1 (ko) 2007-12-03

Family

ID=22658183

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020027009923A Expired - Fee Related KR100781815B1 (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ
KR1020087010742A Ceased KR20080044358A (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ
KR1020077016678A Expired - Fee Related KR100864745B1 (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020087010742A Ceased KR20080044358A (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ
KR1020077016678A Expired - Fee Related KR100864745B1 (ko) 2000-02-02 2001-01-29 리네졸리드 결정 형태 ⅱ

Country Status (30)

Country Link
EP (1) EP1255754B1 (enExample)
JP (1) JP5235256B2 (enExample)
KR (3) KR100781815B1 (enExample)
CN (1) CN1221547C (enExample)
AR (1) AR027261A1 (enExample)
AT (1) ATE297920T1 (enExample)
AU (1) AU782138B2 (enExample)
BR (1) BR0107667A (enExample)
CA (1) CA2395603C (enExample)
CO (1) CO5261555A1 (enExample)
CZ (1) CZ302292B6 (enExample)
DE (1) DE60111497T2 (enExample)
DK (1) DK1255754T3 (enExample)
EA (1) EA004434B1 (enExample)
EE (1) EE05197B1 (enExample)
ES (1) ES2242728T3 (enExample)
HU (1) HUP0301076A3 (enExample)
IL (1) IL151010A0 (enExample)
MX (1) MXPA02007471A (enExample)
MY (1) MY122829A (enExample)
NO (2) NO323459B1 (enExample)
NZ (1) NZ520541A (enExample)
PE (1) PE20011086A1 (enExample)
PL (1) PL356433A1 (enExample)
PT (1) PT1255754E (enExample)
SI (1) SI1255754T1 (enExample)
SK (1) SK287025B6 (enExample)
TW (1) TWI297687B (enExample)
WO (1) WO2001057035A1 (enExample)
ZA (1) ZA200205162B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200088328A (ko) * 2017-11-16 2020-07-22 페르시카 파마슈티컬스 리미티드 리네졸리드 제제

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100490643B1 (ko) * 2002-10-29 2005-05-19 한국과학기술연구원 새로운 메틸리덴 피페리딘일 옥사졸리딘온 유도체 및이들의 제조방법
ES2803516T3 (es) 2003-10-16 2021-01-27 Symed Labs Ltd Una forma cristalina de linezolid
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
EP1658275A1 (en) * 2004-06-29 2006-05-24 Teva Pharmaceutical Industries Ltd Crystalline form iv of linezolid
EP1745028A2 (en) * 2004-06-29 2007-01-24 Teva Pharmaceutical Industries Ltd Solid forms of linezolid and processes for preparation thereof
WO2006091731A2 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
KR20070062504A (ko) * 2005-06-22 2007-06-15 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 말레이트의 다형태
DK1749517T3 (da) * 2005-07-20 2008-11-03 Teva Pharma Stabil farmaceutiske sammensætning af linezolid form IV
WO2007102082A1 (en) * 2006-03-09 2007-09-13 Glenmark Pharmaceuticals Limited High oxazolidinone content solid dosage forms
WO2008127300A2 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2011050826A1 (en) 2009-10-28 2011-05-05 Synthon B.V. Process for making crystalline form a of linezolid
CN103025730A (zh) 2010-04-30 2013-04-03 印第安纳大学研究及科技有限公司 制备利奈唑胺的方法
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
WO2012019632A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Process for making linezolid
EP2593440A1 (en) * 2011-02-24 2013-05-22 Lee Pharma Limited Anhydrous linezolid crystalline form-ii
WO2012119653A1 (en) 2011-03-09 2012-09-13 Synthon Bv Process for making crystalline form a of linezolid
CN102731341A (zh) * 2011-04-13 2012-10-17 上海医药工业研究院 用于制备利奈唑胺的中间体及其制备方法
CN105461648B (zh) * 2011-05-03 2018-01-12 江苏豪森药业集团有限公司 利奈唑胺的晶型及其制备方法
CN102399200B (zh) * 2011-12-14 2013-12-04 浙江新东港药业股份有限公司 一种利用悬浮结晶法制备利奈唑胺晶型ⅰ的方法
WO2013111048A1 (en) 2012-01-24 2013-08-01 Jubilant Life Sciences Limited Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
WO2013120496A1 (en) 2012-02-14 2013-08-22 Pharmathen S.A. Process for the preparation of linezolid in crystalline form and salts thereof
CN102643245A (zh) * 2012-04-10 2012-08-22 杭州华东医药集团生物工程研究所有限公司 一种利奈唑胺晶型及其制备方法
ES2603252T3 (es) 2012-11-09 2017-02-24 Synthon Bv Proceso para preparar linezolid
US20190343761A1 (en) 2016-11-16 2019-11-14 Persica Pharmaceuticals Ltd. Antibiotic formulations for lower back pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
MY115155A (en) * 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
SG85683A1 (en) * 1996-04-11 2002-01-15 Upjohn Co Process to prepare oxazolidinones
NZ504372A (en) * 1997-11-07 2002-12-20 Upjohn Co Process to produce N-[3-fluoro-4(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
미국특허공보 05688792호(1997.11.18)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200088328A (ko) * 2017-11-16 2020-07-22 페르시카 파마슈티컬스 리미티드 리네졸리드 제제
KR102787942B1 (ko) 2017-11-16 2025-03-31 페르시카 파마슈티컬스 리미티드 리네졸리드 제제

Also Published As

Publication number Publication date
SI1255754T1 (sl) 2005-12-31
CN1221547C (zh) 2005-10-05
NO323459B1 (no) 2007-05-14
WO2001057035A1 (en) 2001-08-09
SK9942002A3 (en) 2002-11-06
CZ302292B6 (cs) 2011-02-09
CO5261555A1 (es) 2003-03-31
PT1255754E (pt) 2005-11-30
PL356433A1 (en) 2004-06-28
ZA200205162B (en) 2003-09-29
CA2395603C (en) 2010-03-23
ES2242728T3 (es) 2005-11-16
DK1255754T3 (da) 2005-08-22
MXPA02007471A (es) 2002-12-13
SK287025B6 (sk) 2009-10-07
NO20023654D0 (no) 2002-08-01
AU782138B2 (en) 2005-07-07
EE200200420A (et) 2003-12-15
MY122829A (en) 2006-05-31
CN1394207A (zh) 2003-01-29
JP5235256B2 (ja) 2013-07-10
KR20020072300A (ko) 2002-09-14
JP2003522175A (ja) 2003-07-22
NZ520541A (en) 2004-02-27
EP1255754B1 (en) 2005-06-15
DE60111497T2 (de) 2006-05-18
KR20070087178A (ko) 2007-08-27
EE05197B1 (et) 2009-08-17
ATE297920T1 (de) 2005-07-15
NO20023654L (no) 2002-08-01
HK1051196A1 (en) 2003-07-25
KR100864745B1 (ko) 2008-10-22
PE20011086A1 (es) 2001-10-04
TWI297687B (en) 2008-06-11
KR20080044358A (ko) 2008-05-20
AR027261A1 (es) 2003-03-19
IL151010A0 (en) 2003-02-12
AU3275501A (en) 2001-08-14
NO20065836L (no) 2002-08-01
EA004434B1 (ru) 2004-04-29
HUP0301076A3 (en) 2004-06-28
CA2395603A1 (en) 2001-08-09
EA200200819A1 (ru) 2003-02-27
DE60111497D1 (de) 2005-07-21
HUP0301076A2 (hu) 2003-08-28
CZ20022635A3 (cs) 2002-10-16
EP1255754A1 (en) 2002-11-13
BR0107667A (pt) 2002-10-08

Similar Documents

Publication Publication Date Title
KR100864745B1 (ko) 리네졸리드 결정 형태 ⅱ
US6559305B1 (en) Linezolid—crystal form II
RU2186765C2 (ru) Кристаллические модификации 2-амино-4-(4-фторбензиламино)-1-этоксикарбонил-аминобензола и способ их получения (варианты)
US20080103317A1 (en) Processes for preparation of crystalline mycophenolate sodium
SK2802001A3 (en) Crystalline forms of eto2c-ch2-(r)cgl-aze-pab-oh
US5015646A (en) Pharmaceutically useful polymorphic modification of buspirone
JP2702519B2 (ja) 多形結晶形態の転換法
JPH06192228A (ja) 結晶性（ｒ）−（−）−２−シクロヘプチル−ｎ−メチルスルフオニル−［４−（２−キノリニルメトキシ）−フエニル］−アセトアミド
JP2004536868A (ja) 不整脈治療用のピリダジノン誘導体の多形体塩
EP1384708A1 (en) Process for the manufacture of form I of nolomirole hydrochloride
HK1051196B (en) Linezolid-crystal form ii
CN120923409A (zh) 氟啶虫胺腈的晶型

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

St.27 status event code: A-5-5-P10-P19-oth-PG1701

Patent document republication publication date: 20080414

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1007818150000

Gazette reference publication date: 20071203

FPAY Annual fee payment

Payment date: 20101126

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111128

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111128

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000